- Home
- PHVS vs JANX Comparison
PHVS vs JANX Comparison
Compare PHVS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- JANX
- Stock Information
- Founded
- PHVS 2015
- JANX 2017
- Country
- PHVS Switzerland
- JANX United States
- Employees
- PHVS N/A
- JANX N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- JANX Health Care
- Exchange
- PHVS Nasdaq
- JANX Nasdaq
- Market Cap
- PHVS 1.6B
- JANX 1.4B
- IPO Year
- PHVS 2021
- JANX 2021
- Fundamental
- Price
- PHVS $22.08
- JANX $27.81
- Analyst Decision
- PHVS Buy
- JANX Strong Buy
- Analyst Count
- PHVS 6
- JANX 11
- Target Price
- PHVS $36.50
- JANX $76.55
- AVG Volume (30 Days)
- PHVS 217.1K
- JANX 1.1M
- Earning Date
- PHVS 11-12-2025
- JANX 11-06-2025
- Dividend Yield
- PHVS N/A
- JANX N/A
- EPS Growth
- PHVS N/A
- JANX N/A
- EPS
- PHVS N/A
- JANX N/A
- Revenue
- PHVS N/A
- JANX $439,000.00
- Revenue This Year
- PHVS N/A
- JANX N/A
- Revenue Next Year
- PHVS N/A
- JANX $89.91
- P/E Ratio
- PHVS N/A
- JANX N/A
- Revenue Growth
- PHVS N/A
- JANX N/A
- 52 Week Low
- PHVS $11.51
- JANX $21.73
- 52 Week High
- PHVS $26.33
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- PHVS 49.23
- JANX 60.50
- Support Level
- PHVS $22.38
- JANX $24.30
- Resistance Level
- PHVS $23.64
- JANX $31.59
- Average True Range (ATR)
- PHVS 1.28
- JANX 1.80
- MACD
- PHVS 0.04
- JANX 0.23
- Stochastic Oscillator
- PHVS 61.27
- JANX 59.84
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.